4 ratings / 3.5 average

The Management of Portopulmonary Hypertension

Michael J Krowka, MD

The era of liver transplantation (LT) has refocused attention on the clinical entity of pulmonary arterial hypertension (PAH) associated with portal hypertension from any cause, also known as portopulmonary hypertension (PPH) [1]. Once thought to be caused by pulmonary emboli emanating from blood clots in portocaval pathways, the pathophysiology of PPH now appears to be more complex [2]. Importantly, the implications for patients with PPH considered for LT are evolving, with new pharmacological options and outcomes that suggest that, in highly selected patients, total resolution of this pulmonary vascular abnormality can occur, at least as characterized by right heart catheterization (RHC) and transthoracic echocardiographic function of the right ventricle (RV) [1]. The American Association for the Study of Liver Disease (AASLD) has endorsed formal practice guidelines to screen for PPH in all LT candidates [3].

Return to top


Pharmacotherapeutic Options for Pulmonary Arterial Hypertension
Myung H Park, MD
CML Pulmonary Hypertension
Congenital Heart Disease and Pulmonary Arterial Hypertension: Focus on Eisenmenger’s Syndrome
Julie Wacker and Maurice Beghetti, MD
CML Pulmonary Hypertension
Endothelial Progenitor Cells as a Target for Therapy of Pulmonary Hypertension
Laszlo Farkas, MD1,2,3, and Martin R Kolb, MD, PhD1,2
CML Pulmonary Hypertension
Inflammatory Mechanisms 
in Pulmonary Hypertension
Ali Sadoughi, MD1,2, Yinzhong Zhang MD, PhD1, Edmund J Miller, PhD, FRSC1,3,4, and Arunabh Talwar, MD, FCC P1,2,3,4
CML Pulmonary Hypertension
Noninvasive Imaging in the Evaluation 
of Pulmonary Hypertension
Asghar A Fakhri, MD1, Vikas K Rathi, MD, FACC2, Rachel Hughes-Doichev, MD, FASE1, and Raymond L Benza, MD1
CML Pulmonary Hypertension
Sickle Cell Disease-Associated Pulmonary Hypertension: the Effect of Anemia and High Cardiac Output
Shoaib Alam, MD, and Gregory J Kato, MD
CML Pulmonary Hypertension